Chroma Medicine

Executive Summary

Chroma Medicine is a preclinical-stage biotechnology company pioneering a novel class of genomic medicines based on epigenetic editing. Unlike traditional gene editing approaches that cut DNA, Chroma's platform precisely turns genes on or off without altering the underlying genetic sequence, potentially offering durable, single-dose therapies with an improved safety profile. Founded in 2021 and headquartered in Boston, the company has raised $135 million to advance its epigenetic editing technology for a broad range of diseases. While still in preclinical development, Chroma's platform represents a paradigm shift in gene therapy, aiming to harness the cell's natural regulatory mechanisms for long-lasting therapeutic effects. The company's success hinges on demonstrating in vivo durability and safety, as well as progressing its lead programs toward the clinic.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead epigenetic editing program40% success
• Q4 2026Publication of preclinical in vivo efficacy data in a peer-reviewed journal70% success
• Q3 2026Announcement of a strategic partnership or Series C financing round55% success